Notable Facts
→CFO of publicly traded Disc Medicine (NASDAQ:IRON) with $2+ billion market cap
→Over 30 years of biotech finance leadership experience
→Former CFO at multiple public biotech companies: Replimune Group, Merrimack Pharmaceuticals, Dimension Therapeutics
→16-year veteran at Genzyme Corporation during rapid growth phase
→Board director and Audit Committee Chair at Biodesix (NASDAQ:BDSX)
→Independent board member at VectorY Therapeutics and previously Visioneering Technologies
→Led multiple IPOs and major financing transactions
→Designated 'audit committee financial expert' under SEC regulations
→Age 58, B.A. in Accounting from Hofstra University
→Extensive insider trading disclosures indicating active equity ownership